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Abstract 
The Phytosterol Cyclopamine Rescues Structural and Behavioral Deficits in a 
Drosophila model of Alzheimer’s Disease 
Phuong Nguyen 
Daniel R. Marenda, Ph.D. & Aleister J. Saunders, Ph.D. 
 
Alzheimer's disease (AD), a progressive neurodegenerative disorder, is 
the most common form of dementia. One of the prominent hallmarks of AD is the 
elevated level of amyloid β (Aβ) peptide in brain tissue that has been suggested 
to interfere with cellular homeostasis, and thus disrupt neuronal functions and 
survival. Our previous in vitro study showed that cyclopamine, a naturally 
occurring phytosterol found in corn lily, lowers Aβ level in HeLa cells and primary 
rat cortical neurons. In an independent study, we used our well-characterized 
Drosophila melanogaster model of AD to perform a high-throughput in vivo drug 
screen for a library of 264 GPCR-targeted drugs. We once again identified 
cyclopamine as a suppressor of Aβ-induced changes in Drosophila. Therefore, 
we sought to determine if cyclopamine has a similar mechanism of action in vivo, 
thus can potentially ameliorate other AD-associated phenotypes in our 
Drosophila model. Here, we find that cyclopamine does not significantly alter Aβ 
levels   in these animals. However, cyclopamine is still capable of rescuing the 
losses of synaptic structure and activity, aberrant brain morphology, and memory 
deficits which are central to the pathological progression of AD. Furthermore, we 
observed negative effects of cyclopamine on the wild type animals and other 
Drosophila models of neurodegeneration, indicating that the neuroprotective 
action of cyclopamine could be specific to the context of AD in this Drosophila 
 vii 
 
model. Together, these lines of evidence demonstrate the therapeutic potential of 
cyclopamine that can be further explored for AD drug development. 
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CHAPTER 1: INTRODUCTION 
Alzheimer's disease (AD), the most common form of dementia, is a 
progressive neurodegenerative disorder associated with cognitive decline, 
learning and memory deficits, and neuronal loss predominantly in cerebral cortex 
and hippocampus (Bertram et al., 2010; Nelson et al., 2009; Tanzi and Bertram, 
2005). One of the prominent pathological hallmarks of AD is protein aggregation 
found in brain tissue and neurons. These proteins include aggregates of 
hyperphosphorylated tau found in intracellular neurofibrillary tangles, and 
aggregates of the amyloid β (Aβ) peptides found in extracellular plaques (Nelson 
et al., 2009). Numerous studies have identified genetic risk factors for the 
progression of AD, and these studies continue to show the importance of tau and 
Aβ metabolism in AD onset (Totso and Reitz., 2013). 
The Aβ peptide is generated from the sequential proteolytic cleavage of 
the Amyloid Precursor Protein (APP) by β- and γ-secretases (Bertram and Tanzi, 
2012; Tanzi and Bertram, 2005). At the plasma membrane, full-length APP is 
internalized, cleaved by β-secretase into APP C-terminal fragments (APP-CTFs). 
Through subcellular trafficking to the trans-Golgi network, APP-CTFs are cleaved 
by γ-secretase to generate soluble Aβ peptides (Choy et al., 2012). These 
peptides are then released into the extracellular space and have the potential to 
oligomerize and polymerize into plaques (Choy et al., 2012). Both Aβ oligomers 
and Aβ-containing plaques have been shown to induce oxidative damage, 
neuroinflammation, synaptic dysfunction, neuronal apoptosis and learning and 
memory deficits in the animal models (Bouter et al., 2014; De Felice et al., 2007; 
 2 
 
Harris et al., 1995; Löffler et al., 2014; Tomiyama et al, 2010; Tu et al. 2014; 
Wogulis et al., 2005). 
Transgenic animal models of AD have been extensively studied to dissect 
the mechanisms underlying disease progression, and to explore the potential 
therapeutic approaches (De Felice and Munoz, 2016). We previously created 
and characterized a Drosophila melanogaster model of AD that displays a 
number of phenotypes consistent with human AD, including Aβ buildup, loss of 
synaptic connectivity, aberrant brain morphology, and deficits in memory 
(Chakraborty et al., 2011; Mhatre et al., 2013; Mhatre et al., 2014a; Mhatre et al., 
2014b). These phenotypic defects are reversed by L-685, 458, a potent γ–
secretase inhibitor, suggesting this model is responsive to pharmacological 
intervention (Chakraborty et al., 2011; Mhatre et al., 2014b).  
For that reason, we utilized this Drosophila model to perform a high-
throughput in vivo drug screen for AD, using a library of 264 GPCR-targeted 
molecules (data not published). The potential drug candidates were evaluated by 
the abilities of these drugs to suppress defects in external morphology including 
crumpled wings and/or melanotic masses on the proboscis (Chakraborty et al., 
2011). From this drug screen, we identified cyclopamine, a steroidal alkaloid 
derived from corn lily, as a potential candidate capable of rescuing our AD model 
phenotypes (data not published). In an independent study, we showed that 
cyclopamine decreases Aβ accumulation by sequestering APP-CTFs away from 
γ-secretase, and promotes the accumulation of intracellular APP-CTFs in HeLa 
cells and primary rat cortical neurons (Vorobyeva et al., 2014).  
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Here, we confirm that treating our AD Drosophila model with cyclopamine 
does not recapitulate similar biochemical changes as in mammalian cell culture, 
such as increased level of APP-CTFs and lowered Aβ accumulation. 
Nevertheless, we showed that cyclopamine alleviates a number of the 
phenotypic defects observed in this Drosophila model including neuroanatomical 
abnormalities, synaptic dysfunction, motor deficits, and memory impairment. 
Taken together, these data suggest that cyclopamine possesses neuroprotective 
effects in an in vivo model, are relevant to clinical symptoms in human, and may 
be further investigated for AD therapeutics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
CHAPTER 2: MATERIALS AND METHODS 
2.1 Drosophila stocks and genetics 
All Drosophila stocks and crosses were maintained at 25oC in a 12:12 
light:dark cycle with 60% humidity. Normal food consisted of cornmeal, yeast, 
agar and molasses (Chakraborty et al., 2011). For drug treatments, food was 
prepared from dried instant food (Nutri-Fly Instant from Genesee Scientific) with 
water containing 1.6% of 10% w/v tegosept (methyl p-hydroxybenzoate in 95% 
ethanol) and 0.1% of DMSO vehicle or 100 nM cyclopamine. AD Drosophila were 
raised on drug containing food for their entire lifespan.  
 To drive the expression of transgenes in Drosophila, the Gal4/UAS 
bipartite system was used as previously described (Brand and Perrimon, 1993). 
Drosophila stocks which were purchased from the Bloomington Stock Center 
with stock number referred as BL#. Expression of human APP and BACE in the 
CNS was controlled by the pan-neuronal elav-Gal4 driver (P{GawB}elavC155 
(BL#458)) as previously described. P{UAS-mCD8::GFP.L}LL4, P{hsFLP}1, w* 
(BL#5146) was used to drive membrane tagged expression of GFP in neurons 
for neuroanatomical analysis of Drosophila mushroom bodies, and is referred to 
as elav-CD8-GFP. The P{UAS:APP}; P{UAS:BACE} stock, referred to as APP; 
BACE is previously described (Chakraborty et al., 2011). Control outcrosses 
were generated from elav-Gal4 driver either with or without GFP and w1118 
(BL#3605). Each transgene was heterozygous in all experiments. 
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2.2 Western blot analysis 
 Adult AD Drosophila were kept in drug containing food for 4 days post-
eclosion. For each experimental condition, lysates were prepared from 15-20 
Drosophila heads which were immediately homogenized in RIPA buffer (50 mM 
Tris, 150 mM NaCl, 1% SDS, 1% NP-40, and 0.5% deoxycholate, pH 8.0) 
supplemented with protease inhibitor cocktail (EMD Millipore) and 1mM EDTA. 
The homogenate was spun at 13,000 rpm at 4oC for 25 minutes to collect 
supernatant for immediate analysis or storage at -80oC. Samples for western blot 
were prepared using the 4× NuPage LDS sample buffer (Invitrogen, Inc.) 
containing 0.2% BME (β-Mercaptoethanol, Sigma-Aldrich) and heated to 95 °C 
for 10 minutes. Equal lysate volumes were loaded onto each well of NuPAGE 4–
12% Bis Tris Gel (Invitrogen). Gels were run using MES running buffer and 
transferred to PVDF membrane (Immobilon Millipore) using a semi-dry transfer 
apparatus (Owl Scientific) and NuPage transfer buffer (Invitrogen). After transfer, 
membranes were blocked with 2% BSA PBS blocking buffer for one hour. Next, 
the blocking buffer was removed and the membrane was probed overnight at 4°C 
with blocking buffer containing C1/6.1 C-Terminal antibody (BioLegend) and an 
antibody to β-actin (Sigma; 1:10,000). Membrane was washed four times with 1X 
PBST for five minutes each. Then, the membrane was probed for one hour at 
room temperature with goat anti-mouse 2° antibody (800 nm; LiCor) at 1:10,000 
diluted in blocking buffer. Band intensities were quantified using the Odyssey 
software. 
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2.3 ELISA analysis 
Aβ40 ELISA (294-64701 Wako, Japan) was performed according to the 
manufacturers' instructions. Four days post-eclosion, 100 AD Drosophila heads 
per sample were lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% SDS, 1% 
NP-40, and 0.5% deoxycholate, pH 8.0) and incubated over night at 4°C. 
Samples were analyzed using a luminescence plate reader. All samples were 
done in triplicates. 
 
2.4 Neuromuscular junction analysis 
 Wandering third instar larvae were fillet dissected in PBS, pinned down in 
Sylgard lined Petri dishes, then fixed in 4% paraformaldehyde for 25 minutes as 
described (Mhatre et al., 2014b). Larval body walls were washed with PBS 
containing 0.1% Triton X-100 (PBT), following with a wash with PBS containing 
0.5% Triton X-100. Larval body walls were incubated in PBT containing TRITC-
conjugated Phalloidin at 1:200 (Sigma-Aldrich) to stain for muscles and 
fluorescein- conjugated HRP at 1:50 (Jackson ImmunoResearch Labs) to stain 
for neuronal membranes for 2 hours at 4°C, followed by two 5-minute washes 
with PBT. Dissected larvae were then mounted in Vectashield (Vector Labs, H-
1000). Imaging was performed using an Olympus FluoView FV1000 laser 
scanning confocal microscope. The number of axonal branches, the type of 
branching and the number of synaptic boutons, were quantified using ImageJ 
software as previously described (D'Rozario et al., 2016; Mhatre et al., 2014b). 
The 6/7 NMJ of abdominal hemisegments A3 were used for all studies.  
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2.5 Mushroom body morphology 
 To visualize mushroom body structure, neuronal membrane was tagged 
with GFP (UAS:CD8-GFP) of which expression was driven by elav-Gal4. Six 
days after eclosion, adult Drosophila brains were dissected, fixed in 4% 
paraformaldehyde for 25 minutes, and mounted in vectashield (Vector Labs, H-
1000). The images were taken using confocal microscopy under 200x 
magnification, and the surface areas of the α, β, and γ lobes were measured 
using ImageJ software. About 16-28 brains were analyzed per experimental 
condition. 
 
2.6 Electrophysiology 
Third instar larvae were fillet dissected in Roger’s Ringer (135 mM NaCl, 5 
mM KCl, 4 mM MgCl2*6H2O, 1.8 mM CaCl2*2H2O, 5 mM TES, 72 mM Sucrose, 
2mM glutamate) on Sylgard (World Precision Instruments)-coated coverslips. 
Muscle 6 was clamped at -60 mV using an Axoclamp 900A amplifier (Molecular 
Devices). Both the clamp and recording electrodes were filled with 3 mM KCl and 
used provided they exhibited 10-20 MΩ of resistance. Stimulating electrodes 
were filled with bath saline (Roger’s Ringer). A 0.5 Hz, 10 V stimulus was 
delivered to the segmental nerves by a Grass S88 stimulator with a SIU5 
isolation unit (Grass Technologies). Ten stimuli were delivered separated by 5 
seconds and the mean evoked amplitude was used for each animal. Equal 
numbers of control and experimental recordings were obtained each day. 
Recordings were digitized with a Digidata 1443 digitizer (Molecular Devices). 
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Three minutes of mEJC data were analyzed for each recording. Data were 
analyzed in pClamp (v10.4, Molecular Devices) and GraphPad Prism (v. 5.01). 
 
2.7 Locomotor behaviors 
 Wandering third instar larvae were briefly rinsed with PBS and allowed to 
acclimate for one minute on a 4% agar surface. Then, individual larva was 
transferred into the center of a fresh 100-mm Petri dish containing 4% agar. 
Larval contraction assay was performed on clean and flat agar surface, under a 
constant white light to avoid any chemotactic, geotaxis and phototactic cues. A 
contraction is considered as one full body wall contraction, either forward or 
backward. Using a Leica Mz 125 stereomicroscope, number of contractions was 
manually counted for one minute for each larva. A minimum of 20 larvae was 
analyzed per experimental condition. 
 
2.8 Learning and memory assessment 
Courtship suppression assay was used to access learning and memory 
based on the abilities of Drosophila males to modify their courtship behaviors in 
response to associative conditioning as previously described (Siegel and Hall, 
1979). After 0-6 hours post-eclosion, virgin Drosophila males of each 
experimental condition were collected and transferred to individual food vials of 
appropriate drug treatments. Similarly, virgin wild type (Canton S) females were 
collected and kept in a vial of normal food. These animals were aged for 5 days 
during which time all fly transfers were performed without anesthesia, but using 
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the aspirator. To prepare for the training, half of the virgin Canton S females were 
mated with Canton S males as observed by the experimenter on day fourth.  
On day fifth, a tested virgin male and a mated Canton S female were 
transferred to a partitioned mating chamber (Aktogen) which contains a divider to 
keep the animals separated. This experiment was carried out during the light 
phase at 25°C and 60% humidity, recorded using a Sony DCR-SR47 Handycam 
with Carl Zeiss optics, and illuminated from below using a constant 115V white 
light transilluminator. After 2 minutes of acclimation, the divider was removed to 
expose the tested virgin male to the mated Canton S female for 60 minutes of 
training. Sham males experienced the same manipulations, but were not 
exposed to mated females during the training session. Then, each trained or 
sham male was transferred to a clean partitioned mating chamber containing a 
virgin Canton S female. After a 2-minute resting period, the divider was removed 
and the courtship behaviors of tested male towards the virgin Canton S female 
were monitored for 10 minutes to test immediate recall memory. A total of 10-26 
trained or sham males were assayed per experimental condition. Finally, a 
blinded analysis of courtship behaviors was performed using iMovies software 
(Apple). The courtship index (CI) was calculated as the amount of time that the 
tested male spent performing courting behaviors divided by the total time 
assayed. 
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CHAPTER 3: RESULTS 
3.1 Cyclopamine does not modulate Aβ production in vivo  
 In HeLa cells and cultured primary rat cortical neurons, we demonstrated 
that cyclopamine decreases Aβ40 level by promoting the accumulation of 
intracellular APP-CTFs (Vorobyeva et al., 2014). To determine whether or not 
cyclopamine has similar action on APP metabolism in vivo, we utilized the gal4-
UAS bipartite system to drive expression of human APP695 and BACE1 (β-
secretase) throughout the central nervous system (CNS) of Drosophila 
melanogaster as previously described (Chakraborty et al., 2011; Mhatre et al., 
2014b). The gal4 driver was expressed under the promoter of elav – a neuron 
specific protein.  
We first examined the effect of cyclopamine on the level of APP-CTFs, a 
substrate for Aβ production. In the Western blot analysis of AD Drosophila head 
lysates, the APP-CTFs level was normalized to the full-length human APP and β-
actin to adjust for the differential expression of the transgenic constructs and the 
total protein level respectively. Compared to DMSO treated, cyclopamine treated 
head lysates showed an approximately 10% increase in APP-CTFs, but this 
difference was not statistically significant (Figure 1). Then, we directly measured 
the Aβ level using ELISA analysis for Aβ40 which is a major Aβ isoform from the 
cleavage of neuronal APP695 (Kellett et al., 2010). In agreement with the APP-
CTF measurement, Aβ40 levels in AD Drosophila was not significantly decreased 
with cyclopamine treatment (Figure 2). These biochemical assessments 
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suggested that the suppressive effect of cyclopamine on the external morphology 
of this AD Drosophila model may not be mediated via altering APP metabolism. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cyclopamine does not lead to APP-CTF accumulation in the AD 
Drosophila. Western blot was performed using 2 protein concentrations of AD 
Drosophila head lysates 4 days post-eclosion. APP-CTF level was normalized to 
human APP695 and β – actin loading control. Appl is the Drosophila ortholog of 
human APP. 
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Figure 2. Cyclopamine does not alter Aβ production in the AD Drosophila. 
Level of Aβ40 was measured using ELISA of AD Drosophila head lysates 4 days 
post-eclosion. The averages of triplicates do not show a significant difference 
between DMSO vehicle and cyclopamine treatments. 
 
 
 
3.2 Cyclopamine alleviates neuroanatomical defects in the AD Drosophila 
In AD patients, neurodegeneration is prominent in the hippocampus where 
memories are formed and consolidated, and the hippocampus has been shown 
to be sensitive to Aβ-induced neurotoxicity in many animal models of AD 
(Hensley et al., 1995; Jhoo et al., 2004; Selkoe, 2002; Sultana et al., 2009; 
Walsh et al., 2002). In Drosophila, an area of the brain critical for memory 
consolidation are the mushroom bodies, a paired neuropil structure in higher 
order sensory integration associated with olfactory learning and memory 
(Dubnau and Tully, 2001; Heisenberg et al., 1985; Ito et al., 1997; van 
Swinderen, 2009). 
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We have previously reported that our AD Drosophila model displays a 
significant reduction in the total area of the mushroom body at day sixth of adult 
stage (Chakraborty et al., 2011). Using temperature-controlled late onset 
paradigm of the same transgenic background, we have shown that the loss of 
axon bundles is more rapid than that of the dendrites or the neuronal cell bodies 
in the mushroom bodies (Mhatre et al., 2014a). Given the sensitivity of the 
mushroom body axons to Aβ-induced pathology in our AD Drosophila model, we 
chose to test the effect of cyclopamine on this region of the brain.  
An elav-CD8-GFP transgenic line was used to tag neuronal membrane 
with GFP to visualize the Drosophila brain structures. In the mushroom body, 
axon bundles are organized into α, β, and γ lobes (Figure 3A). Consistent with 
previous finding, there was a decrease in overall mushroom body axonal area 
which includes α, β, and γ lobes in DMSO treated AD compared to the DMSO 
treated elav-CD8-GFP outcross (Figure 4a). However, cyclopamine treatment of 
AD animals significantly increased the overall mushroom body area (Figure 4a). 
Interestingly, we observed that cyclopamine treatment in the outcross of 
elav-CD8-GFP reduced the overall axonal area of the mushroom bodies 
compared to DMSO treatment (Figure 4a). For this reason, we extended our 
analysis to look at the vertical lobes (α) and medial lobes (β and γ) separately in 
order to further understand the effect of cyclopamine on the different axon 
bundles. While there is functional redundancy, γ lobes are primarily associated 
with short-term memory formation (Zars et al., 2000). Even though α and β lobes 
are indispensable for long-term memory, these structures are only required for 
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the retrieval, not formation or consolidation of short-term memory (McGuire et al., 
2001; Pascual and Préat, 2001; Zars et al., 2000).  
Here, we found that the treatment of outcross animals with cyclopamine 
primarily affected the total area of β and γ lobes, with no significant change in α 
lobes (Figure 4b and 4c). On the contrary, there was no difference between 
DMSO treated and cyclopamine treated AD Drosophila in β, and γ lobes (Figure 
4c). Rather, we observed a strong and significant effect on the α lobes (Figure 
4b).  
Taken together, these data supported that cyclopamine is capable of 
rescuing the neuroanatomical defects associated with our AD Drosophila model. 
Additionally, the differential outcomes of cyclopamine treatment between 
outcross control and AD animals suggested that further investigation is 
worthwhile to determine if this protective action of cyclopamine is dependent on 
neuropathological conditions and/or Aβ-induced neurodegeneration in our model 
of AD. 
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Figure 3. Confocal images of Drosophila mushroom bodies 6 days post-
eclosion. elav-CD8-GFP construct was used to tag neuronal membrane with 
GFP for visualization of the mushroom bodies in DMSO treated outcross (A), 
DMSO treated AD (B) and cyclopamine treated AD (C). Predominant loss of 
α lobes (arrow) was observed in AD Drosophila, but not in those animals with 
cyclopamine treatment. 
A 
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C 
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Figure 4a. Cyclopamine rescues size defect of the overall AD mushroom 
body lobes. Statistical analysis was performed using student t-test (n = 16–28). 
 
 
 
Figure 4b. Cyclopamine rescues size defect of the α lobes in AD 
mushroom body. Statistical analysis was performed using student t-test (n = 
16–28). 
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Figure 4c. Cyclopamine induces loss in the area of β and γ lobes in 
outcross mushroom body. Statistical analysis was performed using student t-
test (n = 16–28). 
 
 
 
3.3 Cyclopamine reverses synaptic abnormalities at the larval 
neuromuscular junction in the AD Drosophila  
Analysis of post-mortem brains of AD patients with a range of symptom 
severity showed that the loss of synapses precedes plaque formation and 
neurodegeneration, especially in the neocortex and the hippocampus (Kandan et 
al., 2013; Sze et al., 1997). Furthermore, synaptic dysfunction has a stronger 
correlation to the degrees of cognitive impairment than neurodegeneration does 
(Scheff et al., 2006; Terry et al., 1991). In our previous studies, we have 
demonstrated that our Drosophila model of AD displays a significant loss of 
synaptic structures at the larval neuromuscular junction (NMJ), which is 
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consistent with the synaptic abnormalities observed in other AD models (Mhatre 
et al., 2014b; Terry et al., 1991).  
The Drosophila larval NMJ is commonly utilized as a robust model system 
to evaluate synaptic integrity because of its stereotypical innervation that eases 
the detection of synaptic alterations (Jan and Jan, 1976; Keshishian et al., 1996; 
Lee and Van Vactor, 2003; Long and Van Vactor, 2013; Menon et al., 2013). 
Furthermore, the vast majority of synapses at the Drosophila NMJ is 
glutamatergic (Collins and DiAntonio, 2007). Given that glutamatergic synapses 
make up the majority of mammalian excitatory synapses that are severely 
damaged in AD, treating AD larvae with cyclopamine would provide insights into 
the effects of this drug not only on synaptic morphology in general, but also on 
glutamatergic synapses (Mattson, 2008). 
As we have previously reported, there was a drastic loss of both the total 
number of boutons and the total number of axonal branches in the NMJs of AD 
Drosophila larvae treated with DMSO compared to outcross controls (Mhatre et 
al., 2014b; Figure 6 and 7a). Upon cyclopamine treatment, we observed a 
significant rescue of both the total number of boutons (Figure 6) and branches 
(Figure 7a).  
In addition to measuring total number of axonal branches, we further 
explored the synaptic complexity by categorizing the different branching types 
according to increasing orders from primary and tertiary branches (Budnik et al., 
1990). A primary branch is directly stemmed from the main axonal shaft which is 
a projection of a motor neuron resided in the ventral nerve cord. Secondary and 
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tertiary branches are originated from the primary and secondary branches 
respectively (Budnik et al., 1990). We noted a trend in decreasing the 
percentages of secondary and tertiary branches in DMSO treated AD compared 
to DMSO treated outcross animals (Figure 7b), suggesting that AD Drosophila 
had less complex branching structures. However, cyclopamine treated AD 
Drosophila had higher the percentages of both secondary and tertiary branches 
(Figure 7b). These evidences suggest that cyclopamine may not only restore the 
loss synaptic connections, but also preserve the synaptic complexity in these AD 
animals.  
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Figure 5. Confocal images of the Drosophila NMJ at muscle 6/7 abdominal 
segment 3 in the third instar larvae. FITC-conjugated HRP stains neuronal 
membrane in DMSO treated outcross (A), DMSO treated AD (B) and 
cyclopamine treated AD (C). The significant loss of both knob-like synaptic 
boutons and axonal branches in AD animals was alleviated by cyclopamine. 
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Figure 6. Cyclopamine increases the number of synaptic boutons in AD 
NMJ. Statistical analysis was performed using student t-test (n = 7–12). 
 
 
 
 
Figure 7a. Cyclopamine increases the number of axonal branches in AD 
NMJs. Statistical analysis was performed using student t-test (n = 7–12). 
 
 
0
10
20
30
40
50
60
70
80
DMSO Cyclopamine DMSO Cyclopamine
Outcross AD
B
ou
to
n 
nu
m
be
r 
* 
* 
0
2
4
6
8
10
12
14
16
18
DMSO Cyclopamine DMSO Cyclopamine
Outcross AD
B
ra
nc
hi
ng
 n
um
be
r 
* 
* 
 22 
 
  
Figure 7b. Potential effect of cyclopamine in increasing axonal complexity 
via alteration of branching profile. Statistical analysis using one-way ANOVA 
did not show significance (n = 7-12). 
 
 
 
3.4 Cyclopamine restores neurotransmission at the larval NMJ and the 
corresponding motor behaviors 
It has been shown that neurotransmission is severely impaired in many 
experimental models of AD including Drosophila (Hascup and Hascup, 2015; 
Huang et al., 2013; Palop et al., 2007; Paula-Lima et al., 2013; Selkoe, 2002; 
Zhao et al., 2010). Prior to this study, we had yet to demonstrate this 
pathophysiological condition in our AD Drosophila model. Therefore, we asked 
whether our AD animals displayed synaptic transmission defects, and if so, 
whether cyclopamine treatment had any effect on this functional outcome, given 
its ability to preserve synaptic connectivity.  
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To address this question, we performed a two-electrode voltage clamp for 
muscle 6 of the third instar larvae to evaluate synaptic transmission at the NMJ. 
For this analysis, we used two separate transgenic lines that overexpress either 
low or high levels of human APP and BACE, which we have previously shown to 
display structural abnormalities at the NMJ (Mhatre et al., 2014b). While there 
was no difference in mEJC amplitude in animals expressing low levels of APP; 
BACE (data not shown), there was a significant reduction in mEJC amplitude in 
AD larvae overexpressing high levels of APP; BACE compared with the outcross 
controls (Figure 8). Treatment of these larvae with cyclopamine, however, 
restored mEJC amplitude (Figure 8). Additionally, overexpression of either APP; 
BACE transgenic lines did not exhibit any change in mEJC frequency or eEJC 
amplitude (data not shown). These data indicated that cyclopamine attenuates 
the defects in spontaneous synaptic transmission of Drosophila larvae 
expressing high level of APP and BACE. 
Since proper neurotransmission at the NMJ is required for locomotor 
behaviors in Drosophila larvae, we next examined whether cyclopamine rescues 
the motor deficits that are associated with this AD model (Borst et al., 2005; 
Mhatre et al., 2014b; Sinadinos et al., 2012). By measuring the number of larval 
body-wall contractions during one-minute time frame, we observed a profound 
decrease in contractions of AD larvae treated with DMSO, that was moderately 
but significantly improved with cyclopamine treatment (Figure 9). This behavioral 
response was consistent with the modest rescue at the level of 
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neurotransmission. Furthermore, we again found cyclopamine exerting negative 
effects on the outcross control (Figure 9). 
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Figure 8. Cyclopamine treatment maintains proper spontaneous 
neurotransmission at the AD Drosophila NMJ. Electrophysiology was 
evaluated using two-electrode voltage clamp for muscle 6 of the third instar 
larvae. 
 
 26 
 
 
Figure 9. Cyclopamine decreases the number of larval contractions in the 
outcross but increases in the AD animals. Statistical analysis was performed 
using student t-test (n = 27-51). 
 
 
 
3.5 Cyclopamine rescues immediate recall memory deficits in the AD 
Drosophila model 
Genetic and chemical manipulations in the Drosophila mushroom bodies 
have been shown to disrupt olfactory learning and memory (Belle and 
Heisenberg, 1994; Davis et al., 1996; Owald et al., 2015). In this study, we have 
demonstrated that cyclopamine is able to reserve the mushroom body defects in 
the AD Drosophila. With this structural rescue, we then evaluated the effect of 
cyclopamine on AD Drosophila learning and memory abilities using the courtship 
suppression assay. 
This assay measures associative learning, in which the stereotypical 
courtship behaviors of virgin Drosophila male are modified by exposure to a 
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previously mated female that is unreceptive to courting (Siegel and Hall, 1979; 
Siwicki et al., 2005). Over an hour of training, the male courtship behaviors are 
suppressed as the male learns to associate several odor and behavioral cues 
from the mated female with the failure to copulate. Therefore, when exposed to a 
receptive virgin female, the trained male will court less frequently than sham-
trained males if the trained male has in tact memory (Siegel and Hall, 1979). We 
have previously shown that our AD Drosophila model has normal learning, but 
compromised immediate recall (2 minute) memory (Chakraborty et al., 2011; 
Mhatre et al., 2014a). 
To access learning ability, we compared the courtship indices between the 
initial and the final 10 minutes of the one-hour training. Across all experimental 
conditions, there was a significant decrease in courtship behaviors in the final 10 
minutes of training compared to the initial 10 minutes, indicating the learning 
remained in tact in both outcross controls and AD animals (Figure 10a). 
Within the same experimental condition, we compare the trained males 
with sham-trained males to evaluate memory. In the DMSO treated outcross 
control, there was a decrease in courtship behaviors in the trained compared to 
sham-trained animals (Figure 10b). However, DMSO treatment in the AD model 
showed no significant difference between trained and sham-trained animals 
(Figure 10b), indicating no memory of previous training. Treatment of AD 
Drosophila with cyclopamine significantly improved memory retrieval as there 
was a significant decrease in courtship behavior after training (Figure 10b). In 
addition, we found that cyclopamine induces mild memory loss in the outcross 
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control (Figure 10b). Taken together, these data suggest that cyclopamine 
treatment is capable of rescuing the memory deficits that are associated with our 
Drosophila model of AD. 
 
 
 
 
Figure 10a. All experimental conditions do not after the normal learning 
behaviors associated with courtship. Courtship index represents the amount 
of time that tested male Drosophila spent courting with the female. After an hour 
of training, the initial 10 minutes were compared with the final 10 minutes for 
learning analysis. Both outcross and AD animals displayed normal learning ability 
regardless of drug treatment. Statistical analysis was performed using student t-
test (n = 10-26). 
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Figure 10b. Cyclopamine rescues immediate recall memory deficits in the 
AD Drosophila model but induces memory loss in the outcross animals. 
Courtship index represent the amount of time that tested male Drosophila spent 
courting with the female. After an hour of training followed by 2 minutes of 
resting, both DMSO treated AD and cyclopamine treated outcross animals failed 
to retrieve memory. Statistical analysis was performed using student t-test (n = 
10-26). 
 
 
 
3.6 Cyclopamine does not produce general neuroprotective effects 
Because cyclopamine appeared to be protective for the AD animals but 
detrimental to the outcross control, we asked whether the observed rescue 
effects of cyclopamine is specific to our AD Drosophila or if cyclopamine could 
also be neuroprotective to other neurodegenerative disease models. Using the 
same elav-Gal4 driver, we overexpressed Sod1, Parkin and 128Q human 
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huntingtin proteins in the Drosophila CNS to test the effects of cyclopamine in the 
models of amyotrophic lateral sclerosis (ALS), Parkinson’s (PD) and Huntington’s 
(HD) diseases respectively. Similar to the DMSO treated AD larvae, DMSO 
treated ALS and HD larvae showed similar contraction deficits compared with the 
DMSO treated outcross control (Figure 9 and 11). While Cyclopamine did not 
have effect on Sod1 expressing larvae, it reduced the number of contractions of 
both Parkin and Htt128Q expressing larvae (Figure 11). Taken together, these 
data suggest that the rescue we observe with cyclopamine in our AD Drosophila 
is not the result of general neuroprotective effects of cyclopamine, but may be 
specific to this AD model. 
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Figure 11. Cyclopamine does not possess similar rescue effects in larval 
contraction of other Drosophila models of neurodegeneration. Drosophila 
model of ALS, PD and HT were obtained from paneuronal expression of Sod1, 
Parkin and Htt128Q respectively. Statistical analysis was performed using 
student t-test (n = 20-30). 
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CHAPTER 4: DISCUSSION 
Previously, we have shown that treatment of mammalian cells with 
cyclopamine produces an accumulation of APP-CTFs, and a decrease of 
Aβ peptides (Vorobyeva et al., 2014). Here, we show that treatment of a 
Drosophila model of AD with cyclopamine does not lead to similar biochemical 
changes, but significantly rescues a number of the phenotypes associated with 
this AD model, including synaptic loss, disturbed neurotransmission, motor 
dysfunction, aberrant mushroom body structure and memory deficits. Across 
these assessments, we observed that structural rescue is positively correlated 
with the functional outcome in cyclopamine treated AD animals.  
Strikingly, treatment of outcross control with cyclopamine often results in 
deleterious effects. This is consistent with cyclopamine acting as a teratogen and 
a toxic agent (Lipinski et al., 2008). Additionally, cyclopamine treatment in 
Drosophila models of ALS, Parkinson’s disease, and Huntington’s disease either 
had no effect, or induced defects in larval motor functions (Figure 11). Together, 
this evidence suggests that the neuroprotective effects of cyclopamine may be 
context-dependent, possibly on the overexpression of human APP695 and β-
secretase in our Drosophila model of AD. In the outcross control, the adverse 
effects are observed in larval contractions, the mushroom body size, and 
immediate recall memory. These assays take into account the integration of 
multiple neural circuits, in which the rescue or the negative effects of 
cyclopamine may indicate a moderate action of this drug on individual circuits, 
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but collectively more significant impacts at the level of organismal complexity and 
behavior.  
Under normal physiological condition, the role of Aβ has not been clearly 
characterized, but it has been suggested to be essential for synaptic plasticity, 
memory consolidation, cholesterol homeostasis, and antioxidant activity and 
antimicrobial activity (Vassar, 2014). Although γ-secretase has been a promising 
target due to the direct inhibition of Aβ production, there are negative 
consequences since γ-secretase also plays an important role in Notch signaling, 
a pathway important for multiple neuronal functions. Adult mice heterozygous for 
notch1 displayed defects in spatial learning and memory (Costa et al., 2003). 
Similarly, γ-secretase knockout in mice caused neuronal dysfunction and 
neurodegenerative phenotypes (Saura et al., 2004).  In addition, γ-secretase 
inhibitors often cause undesirable off-target effects such as hyperplasia of goblet 
cells in the gastrointestinal tract due to Notch dysregulation (Basi et al., 2014). 
Semagacestat, a γ-secretase inhibitor, was terminated in phase three clinical 
trials due to declines in cognitive scores as well as adverse side effects such as 
weight loss, altered immune cell composition, skin cancer and infections (Doody 
et al., 2013). Because it is challenging to target γ-secretase without interfering 
with normal cellular processes, modulating the accessibility of APP-CTFs to γ-
secretase is a potentially more specific approach to lower Aβ production. We 
have previously shown that cyclopamine diverts APP-CTFs away from γ-
secretase, while not altering protein homeostasis nor enzymatic activity of γ-
secretase in vitro (Vorobyeva et al., 2014).  
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Although cyclopamine rescues structural and functional deficits in our 
Drosophila model of AD, it does not alter APP metabolism as seen in mammalian 
cell culture. However, the key of our findings is the potential neuroprotective 
effects of cyclopamine in an in vivo nervous system. This may suggest that 
cyclopamine does not strictly lower Aβ production, but possesses multiple modes 
of action such as acting on Aβ-induced pathological changes. AD exhibits 
complex changes in neuronal homeostasis and circuitry that is unlikely to be 
addressed by modulating Aβ alone (Canter et al., 2016). However, if cyclopamine 
does affect APP metabolism in an in vivo mammalian model of AD, the reduction 
of Aβ level coupled with the modifications of Aβ-induced pathological changes 
may lead to a more robust rescue.  
Cyclopamine specifically antagonizes smoothened receptor of the 
vertebrate sonic hedgehog signaling (SHH), a critical pathway for animal 
development (Chen et al., 2002; Incardona et al., 1998). Hedgehog signaling in 
Drosophila and SHH signaling in vertebrates are highly conserved, and most of 
the proteins involved in vertebrate SHH signaling have their functional 
homologues in Drosophila (Varjosalo et al., 2006). However, small molecule 
inhibitors such as cyclopamine that target transmembrane domain of 
smoothened, significantly downregulate mammalian SHH, but not Drosophila 
hedgehog signaling (Varjosalo et al., 2006). Interestingly, we still observed the 
neuroprotective effects of cyclopamine on this AD Drosophila model. For that 
reason, it is important to determine whether the effects of cyclopamine on AD 
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phenotypes is dependent on smoothened and/or hedgehog signaling in 
Drosophila model.  
From this study, we suggest that cyclopamine is neuroprotective in our 
Drosophila model of AD, however, the mechanism of action remains unclear. 
Thus, dissecting the molecular targets that cyclopamine exerts the rescue effects 
on our Drosophila model of AD may potentially expose novel modulators for 
future AD drug development.  
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